


EUROPEAN SUMMITTHE ROLE OF VACCINES AND DIAGNOSTICS IN ADDRESSING AMR

8-9 JUNE 2017QEII CONFERENCE CENTRE, LONDON

PROGRAMME



0900	REGISTRATION AND REFRESHMENTS
1020	Welcome and opening remarks
1030	KEYNOTE PRESENTATION Antimicrobial Resistance – where to next? Professor John Watson, Deputy Chief Medical Officer, Department of Health, London
	PLENARY SESSION HOW CAN VACCINES AND DIAGNOSTICS TO HELP WIN THE BATTLE AGAINST ANTIMICROBIAL RESISTANCE?
1100	Update on the potential and actual role of vaccines in reducing antimicrobial resistance Dr David McIntosh, Honorary Clinical Senior Lecturer, Imperial College, London
1125	Diagnostics Dr Fiona Carragher, Deputy Chief Scientific Officer, NHS England, London
1150	Q&A
1200	REFRESHMENTS, NETWORKING & POSTER VIEWING
1230	PARALLEL SESSIONS 1 DIAGNOSTIC SOLUTIONS FOR ANTIMICROBIAL RESISTANCE (AMR): IDENTIFYING UNMET CLINICAL NEEDS
1230	2 INVITED PAPERS: 4 X 15 MINUTES FOCUSSED ON VACCINES
1330	LUNCH, NETWORKING & POSTER VIEWING
1430	Sponsored session
1515	PARALLEL SESSIONS 1 AMR RAPID DIAGNOSTIC TESTS: NEEDS, TARGET PRODUCT PROFILES AND TECHNOLOGIES Clinical need Professor Hermann Goossens, University of Antwerp
1535	Target Product Dr Cassandra Kelly, Head of AMR & Outbreak, Foundation for Innovative New Diagnostics (FIND)
1555	Technologies: Overview of emerging technologies
1605	(A) ImmunoPoC and Minicare HCL: 15 minute fingerprick test for level and type of infection Dr Liran Shani, ImmunoPOC
1615	(B) Pulmocheck: Test for bacterial infection
1625	



PROGRAMME - 8 JUNE 2017 QEII CONFERENCE CENTRE, LONDON

1515	2 REDUCING ANTIBIOTIC USAGE THROUGH ROUTINE VACCINATION PROGRAMMES The potential impact of a Group B streptococcus vaccine on the use of perinatal antibiotics Professor Paul Heat, Professor of Paediatric Infectious Diseases, St George's Hospital, London
1535	Impact of the childhood influenza programme on disease burden in the elderly Dr Richard Pebody, Head, Influenza and Other Respiratory Virus Surveillance Section, Public Health England, London
1535	Staph aureus vaccines Dr David Wyllie, Senior Clinical Research Fellow, Group Head / Pl, Consultant Physician, Member of congregation and Supervisor, University of Oxford, Oxford
1515	3 REDUCING ANTIBIOTIC USAGE THROUGH ROUTINE VACCINATION PROGRAMMES Whats new in antifungal susceptibility testing Professor Malcolm Richardson
1540	Development of disc diffusion test for anaerobes Mr Trefor Morris
1605	Colistin resistance: our last hope Dr Lim Jones
1605	Discussion
1645	REFRESHMENTS, NETWORKING & POSTER VIEWING
1715	PARALLEL SESSIONS 1 ROUTINE AND RAPID SURVEILLANCE SYSTEMS What surveillance do we have for AMR? Dr Berit Muller-Peabody, Public Health England, London
1735	Why is surveillance important after introducing vaccines? Dr Michael Edelstein, Immunisation, Hepatitis and Blood Safety Department, National Infection Service, London
1755	Rapid surveillance in emergency situations: The Zika Experience
1815	Legacy planning - what did we learn from Ebola? Dr Timothy Brookes, Public Health England, Porton Down, Salisbury
1835	Q&A
1715	2 NEXT GENERATION ANTIMICROBIAL SUSCEPTIBILITY TESTING OF BACTERIA - THE ROLE OF WHOLE GENOME SEQUENCING Rapid susceptibility testing: new phenotypic and non-WGS genotypic approaches Dr Oskar Ekelund, Department of Clinical Microbiology and the EUCAST Development Laboratory,
	Kronoberg Region, Central Hospital, Växjö, Sweden
1745	WGS-based susceptibility testing for TB: from research to service delivery Professor Grace Smith, Deputy Director, PHE London
1815	Should WGS be used for susceptibility testing of bacteria other than TB? Dr Matthew Ellington, Principal Clinical Scientist / Project Manager, PHE London



PROGRAMME - 9 JUNE 2017 QEII CONFERENCE CENTRE, LONDON

0730 BREAKFAST / COFFEE / TEA / BAGEL

CLINICAL LESSONS

0800 Invited papers: 4 x 15 minutes focussed on diagnostics

PLENARY SESSION

ANTIMICROBIAL SUSCEPTIBILITY TESTING

- 0900 Invited Lecture Antimicrobial susceptibility testing then, now and the future

 Dr Derek Brown, Scientific Secretary, European Committee on Antimicrobial Susceptibility Testing
- 0940 Q&A: What next for EUCAST?

Professor Gunnar Kahlmeter, Past- Chair/Technical Data Co-ordinator and Dr Derek Brown, Scientific Secretary, European Committee on Antimicrobial Susceptibility Testing

PARALLEL SESSIONS

- 1 AMR RAPID DIAGNOSTIC TESTS: DEVELOPMENT ROADMAPS, BUSINESS MODELS AND BEHAVIOUR CHANGE
- 0950 Development Roadmap

Dr Alex Van-Belkum, Corporate Vice President, bioMerieux

- 1010 Business Models
- 1030 Behaviour Change

Dr John Hays, Associate Professor, Erasmus University Medical Centre (Erasmus MC), Rotterdam, The Netherlands

- 2 VACCINE ACCESS AND UPTAKE: THE GLOBAL CHALLENGE
- 0950 HPV vaccine and current controversies about vaccine uptake

Professor Margaret Stanley, Director of Research, Pathology, University of Cambridge

1020 Malaria Vaccine Initiative

Professor Didier Raoult, Aix-Marseille Université, Marseille, France

- 1050 **Q&A**
- 1100 REFRESHMENTS, NETWORKING & POSTER VIEWING
- 1130 Sponsored symposium one
- 1130 Sponsored symposium Two

PLENARY KEYNOTE LECTURE

1215 Pneumococcal vaccine programme

Professor Keith Klugman, The Bill and Melinda Gates Foundation

PROGRAMME - 9 JUNE 2017QEII CONFERENCE CENTRE, LONDON

1300 LUNCH, NETWORKING & POSTER VIEWING

PARALLEL SESSIONS

- 1 THE QUIET REVOLUTION: THE MODERNISATION OF LABORATORIES OPTIMAL USE OF EXISTING DIAGNOSTICS
- Point of care testing lessons from procalcitonin
- 1405 MALDI-TOF and its impact on patient care

Dr Savita Gossain, Consultant Medical Microbiologist, Birmingham Heartlands Hospital

1425 Syndromic approaches to infection detection - tacman microarrays

Dr Martin Curran, Clinical Microbiology and Public Health Laboratory, Public Health England, Addenbrooke's Hospital, Cambridge

- **2** VACCINES AGAINST ANTIBIOTIC RESISTANCE ORGANISMS
- 1345 Typhoid vaccine

Professor Andrew Pollard, Professor of Paediatric Infection and Immunity, University of Oxford, Oxford

- 1405 New TB vaccines
- 1425 HIV vaccine

Professor Sarah Rowland-Jones, Professor of Immunology, Nuffield Department of Medicine, University of Oxford

PLENARY SESSION

AMR GAME CHANGERS: NEXT GENERATION VACCINES AND DIAGNOSTICS

1445 Emerging and experimental vaccines: Vaccinating against MRSA, e-Coli and C-Diff - where are we now?

Diagnostics - the next best things and more

1545 CLOSING REMARKS

